Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1748]

Prognostic model of all-cause mortality at 30 days in patients with cancer and...

Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 ( Dr Chris Labaki - Dana-Farber Cancer Institute, Boston, USA )

Working to improve global cancer care access in low middle-income countries

Dr Julie Gralow, Prof Eduardo Cazap

Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )

Isatuximab + Pd in Difficult-to-Treat Patients with RRMM

Dr Maximilian Merz - Leipzig University, Leipzig, Germany

Isatuximab + Pd in Difficult-to-Treat Patients with RRMM ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )

The advances in the management of patients with Hodgkin lymphoma and non...

Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute...

The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma ( Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florida, USA )

Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly...

Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain

$Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )$

Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial

Dr Maximilian Merz - Leipzig University, Leipzig, Germany

Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )

Cancer patient symptom and physical function reporting by caregivers used as...

Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco...

Cancer patient symptom and physical function reporting by caregivers used as predictors of adverse clinical outcomes ( Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco, USA )

Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic...

Dr Carol Moreno - University of Barcelona, Barcelona, Spain

Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS ( Dr Carol Moreno - University of Barcelona, Barcelona, Spain )

CAR-T cell therapy targeting BCMA is highly effective for patients with...

Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain

$CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )$

A bispecific antibody talquetamab shows promising efficacy in relapsed...

Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands

$A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )$

Ponatinib and blinatumomab shows complete molecular response for patients with...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Subcutaneous isatuximab administration in combination with pomalidomide...

Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia

Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )

More from ecancer